{"id":"bl-1020-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BL 1020 selectively blocks dopamine D3 receptors, which are implicated in reward processing, motivation, and psychotic symptoms. By antagonizing D3 receptors while having minimal activity at D2 receptors, the drug aims to provide antipsychotic efficacy with potentially improved tolerability compared to conventional antipsychotics that broadly block D2 receptors.","oneSentence":"BL 1020 is a dopamine D3 receptor antagonist that modulates dopaminergic signaling in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:24:42.335Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"}]},"trialDetails":[{"nctId":"NCT00722176","phase":"PHASE2","title":"Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-06","conditions":"Schizophrenia","enrollment":220},{"nctId":"NCT00567710","phase":"PHASE2","title":"A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00480571","phase":"PHASE2","title":"Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2007-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BL 1020 High Dose","genericName":"BL 1020 High Dose","companyName":"BioLineRx, Ltd.","companyId":"biolinerx-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BL 1020 is a medication being studied for the treatment of schizophrenia and schizoaffective disorder. It has been compared to risperidone and a placebo in a six-week, randomized, double-blind, placebo-controlled study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}